BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weintraub D, Mamikonyan E. The Neuropsychiatry of Parkinson Disease: A Perfect Storm. Am J Geriatr Psychiatry 2019;27:998-1018. [PMID: 31006550 DOI: 10.1016/j.jagp.2019.03.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang S, Ma Y. Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms. World J Psychiatry 2022; 12(9): 1127-1140 [DOI: 10.5498/wjp.v12.i9.1127] [Reference Citation Analysis]
2 Zhu R, Li Y, Chen L, Wang Y, Cai G, Chen X, Ye Q, Chen Y. Total Burden of Cerebral Small Vessel Disease on MRI May Predict Cognitive Impairment in Parkinson’s Disease. JCM 2022;11:5381. [DOI: 10.3390/jcm11185381] [Reference Citation Analysis]
3 Ghosh D, Singh A, Kumar A, Sinha N. High mobility group box 1 (HMGB1) inhibition attenuates lipopolysaccharide-induced cognitive dysfunction and sickness-like behavior in mice. Immunol Res 2022. [PMID: 35670903 DOI: 10.1007/s12026-022-09295-8] [Reference Citation Analysis]
4 Interian A, Miller RB, Hill LMS, Latorre M, King AR, Rodriguez KM, Mann SL, Kashan RS, Dissanayaka NN, Dobkin RD. A Pilot Study of Telehealth Mindfulness-Based Cognitive Therapy for Depression in Parkinson’s Disease. J Geriatr Psychiatry Neurol. [DOI: 10.1177/08919887221103579] [Reference Citation Analysis]
5 Mori A, Chen JF, Uchida S, Durlach C, King SM, Jenner P. The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease. Molecules 2022;27:2366. [PMID: 35408767 DOI: 10.3390/molecules27072366] [Reference Citation Analysis]
6 Kumari M, Anji A. Small but Mighty-Exosomes, Novel Intercellular Messengers in Neurodegeneration. Biology (Basel) 2022;11:413. [PMID: 35336787 DOI: 10.3390/biology11030413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Klostermann F, Ehlen F, Tiedt HO. Effects of thalamic and basal ganglia deep brain stimulation on language-related functions - Conceptual and clinical considerations. Eur J Paediatr Neurol 2022;37:75-81. [PMID: 35149269 DOI: 10.1016/j.ejpn.2022.01.013] [Reference Citation Analysis]
8 Szymkowicz SM, Jones JD, Timblin H, Ryczek CA, Taylor WD, May PE. Apathy as a Within-Person Mediator of Depressive Symptoms and Cognition in Parkinson's Disease: Longitudinal Mediation Analyses. Am J Geriatr Psychiatry 2021:S1064-7481(21)00546-7. [PMID: 34922823 DOI: 10.1016/j.jagp.2021.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Onofrj M, Di Iorio A, Carrarini C, Russo M, Franciotti R, Espay AJ, Boylan LS, Taylor JP, Di Giannantonio M, Martinotti G, Valente EM, Thomas A, Bonanni L, Delli Pizzi S, Dono F, Sensi S. Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease. Mov Disord 2021. [PMID: 34427338 DOI: 10.1002/mds.28745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Namdev V, Haneef G, Khan AT, Basith SA, Virani A, Canenguez Benitez JS, Sejdiu A, Mathialagan K, Majumder P. Psychiatric Comorbidities Affect the Hospitalization Course of Parkinson's Disease Patients: A Cross-Sectional Inpatient Study. Cureus 2021;13:e16255. [PMID: 34373816 DOI: 10.7759/cureus.16255] [Reference Citation Analysis]
11 Weiss D, Volkmann J, Fasano A, Kühn A, Krack P, Deuschl G. Changing Gears - DBS For Dopaminergic Desensitization in Parkinson's Disease? Ann Neurol 2021. [PMID: 34235776 DOI: 10.1002/ana.26164] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
12 Pham Nguyen TP, Abraham DS, Thibault D, Weintraub D, Willis AW. Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? BMC Neurol 2021;21:240. [PMID: 34167473 DOI: 10.1186/s12883-021-02265-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Milán-Tomás Á, Fernández-Matarrubia M, Rodríguez-Oroz MC. Lewy Body Dementias: A Coin with Two Sides? Behav Sci (Basel) 2021;11:94. [PMID: 34206456 DOI: 10.3390/bs11070094] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Decourt M, Jiménez-Urbieta H, Benoit-Marand M, Fernagut PO. Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents. Biomedicines 2021;9:684. [PMID: 34204380 DOI: 10.3390/biomedicines9060684] [Reference Citation Analysis]
15 Grosso Jasutkar H, Yamamoto A. Do Changes in Synaptic Autophagy Underlie the Cognitive Impairments in Huntington's Disease? J Huntingtons Dis 2021;10:227-38. [PMID: 33780373 DOI: 10.3233/JHD-200466] [Reference Citation Analysis]
16 Elefante C, Brancati GE, Bacciardi S, Mazzucchi S, Del Prete E, Palermo G, Frosini D, Bonuccelli U, Ceravolo R, Lattanzi L, Maremmani I, Perugi G. Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease. J Clin Med 2021;10:2302. [PMID: 34070549 DOI: 10.3390/jcm10112302] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Montanaro E, Artusi CA, Rosano C, Boschetto C, Imbalzano G, Romagnolo A, Bozzali M, Rizzone MG, Zibetti M, Lopiano L. Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic. Neurol Sci 2022;43:341-8. [PMID: 33948763 DOI: 10.1007/s10072-021-05286-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Hong CT, Tan S, Huang TW. Psychotherapy for the Treatment of Anxiety and Depression in Patients with Parkinson Disease: A Meta-Analysis of Randomized Controlled Trials. J Am Med Dir Assoc 2021:S1525-8610(21)00340-6. [PMID: 33957132 DOI: 10.1016/j.jamda.2021.03.031] [Reference Citation Analysis]
19 Martyna MR, Trapp NT, Kratter IH. Can (or Should) We Treat Depression and Anxiety in Parkinson's Disease Algorithmically? Am J Geriatr Psychiatry 2021;29:541-3. [PMID: 33824056 DOI: 10.1016/j.jagp.2021.03.001] [Reference Citation Analysis]
20 Dobkin RD, Mann SL, Weintraub D, Rodriguez KM, Miller RB, St Hill L, King A, Gara MA, Interian A. Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment. Mov Disord 2021. [PMID: 33710659 DOI: 10.1002/mds.28548] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Abou Kassm S, Naja W, Haddad R, Pelissolo A. The Relationship Between Anxiety Disorders and Parkinson's Disease: Clinical and Therapeutic Issues. Curr Psychiatry Rep 2021;23:20. [PMID: 33660146 DOI: 10.1007/s11920-021-01229-9] [Reference Citation Analysis]
22 Hinkle JT, Pontone GM. Psychomotor processing and functional decline in Parkinson's disease predicted by the Purdue Pegboard test. Int J Geriatr Psychiatry 2021;36:909-16. [PMID: 33426751 DOI: 10.1002/gps.5492] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Hinkle JT, Perepezko K, Mills KA, Pontone GM. Attentional dysfunction and the punding spectrum in Parkinson's disease. Parkinsonism Relat Disord 2021;84:23-8. [PMID: 33545553 DOI: 10.1016/j.parkreldis.2021.01.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kenangil G, Demir M, Tur E, Domac F. Alexithymia, depression, and cognition in patients with Parkinson's disease. Acta Neurol Belg 2021. [PMID: 33453039 DOI: 10.1007/s13760-020-01581-2] [Reference Citation Analysis]
25 Kuusimäki T, Al‐abdulrasul H, Kurki S, Hietala J, Hartikainen S, Koponen M, Tolppanen A, Kaasinen V. Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders. Mov Disord 2021;36:1353-61. [DOI: 10.1002/mds.28484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Talaslahti T, Ginters M, Kautiainen H, Vataja R, Elonheimo H, Erkinjuntti T, Suvisaari J, Lindberg N, Koponen H. Criminal Behavior in the Four Years Preceding Diagnosis of Neurocognitive Disorder: A Nationwide Register Study in Finland. Am J Geriatr Psychiatry 2021;29:657-65. [PMID: 33334647 DOI: 10.1016/j.jagp.2020.11.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Khedr EM, Abdelrahman AA, Elserogy Y, Zaki AF, Gamea A. Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life. Egypt J Neurol Psychiatry Neurosurg 2020;56. [DOI: 10.1186/s41983-020-00253-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Li S, Jiao R, Zhou X, Chen S. Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2020;99:e19642. [PMID: 32358345 DOI: 10.1097/MD.0000000000019642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
29 Kuspinar A, Mate KKV, Lafontaine AL, Mayo N. Validation of an Individualized Measure of Quality of Life, Patient Generated Index, for Use with People with Parkinson's Disease. Neurol Res Int 2020;2020:6916135. [PMID: 32292601 DOI: 10.1155/2020/6916135] [Reference Citation Analysis]
30 Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M; Parkinson’s Progression Markers Initiative. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Ann Clin Transl Neurol 2020;7:449-61. [PMID: 32285645 DOI: 10.1002/acn3.51022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
31 Napier TC, Kirby A, Persons AL. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2020;102:109942. [PMID: 32272129 DOI: 10.1016/j.pnpbp.2020.109942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
32 Dobkin RD, Mann SL, Gara MA, Interian A, Rodriguez KM, Menza M. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial. Neurology 2020;94:e1764-73. [PMID: 32238507 DOI: 10.1212/WNL.0000000000009292] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 9.5] [Reference Citation Analysis]
33 Aumann MA, Stark AJ, Hughes SB, Lin YC, Kang H, Bradley E, Zald DH, Claassen DO. Self-reported rates of impulsivity in Parkinson's Disease. Ann Clin Transl Neurol 2020;7:437-48. [PMID: 32227451 DOI: 10.1002/acn3.51016] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
34 Polo-Morales A, Alcocer-Salas Á, Rodríguez-Violante M, Pinto-Solís D, Solís-Vivanco R, Cervantes-Arriaga A. Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease. J Geriatr Psychiatry Neurol 2021;34:60-5. [PMID: 32027207 DOI: 10.1177/0891988720901787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Rossi M, Farcy N, Starkstein SE, Merello M. Nosology and Phenomenology of Psychosis in Movement Disorders. Mov Disord Clin Pract 2020;7:140-53. [PMID: 32071931 DOI: 10.1002/mdc3.12882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
36 Zhou Z, Müller MLTM, Kanel P, Chua J, Kotagal V, Kaufer DI, Albin RL, Frey KA, Bohnen NI. Apathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive decline. Neurology 2020;94:e376-83. [PMID: 31732566 DOI: 10.1212/WNL.0000000000008683] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Friedman JH. Commentary on "The Neuropsychiatry of Parkinson's Disease: A Perfect Storm". Am J Geriatr Psychiatry 2019;27:1019-21. [PMID: 30987802 DOI: 10.1016/j.jagp.2019.03.007] [Reference Citation Analysis]